Phase II Study of Rituximab (NSC 687451) + CHOP Followed by 90Y-Ibritumomab Tiuxetan (NSC 710085) in Patients With Previously Untreated Mantle Cell Lymphoma

Inclusion Criteria

DISEASE CHARACTERISTICS:

- Histologically confirmed mantle cell lymphoma with expression of bcl-1 and CD20

- Stage II-IV disease

- Measurable or evaluable disease

- Measurable disease defined as at least 1 bidimensionally measurable lesion at
least 2 cm by imaging scan

- A spleen at least 17 cm or having discrete filling defects by CT scan will
constitute evaluable disease provided that no explanation other than
lymphomatous involvement (e.g., portal hypertension or other liver disease) is
likely

- No known CNS lymphoma

PATIENT CHARACTERISTICS:

Age

- 18 and over

Performance status

- ECOG 0-2

Life expectancy

- At least 6 months

Hematopoietic

- WBC greater than 2,500/mm^3*

- Platelet count greater than 100,000/mm^3* NOTE: *Unless due to disease in bone marrow

Hepatic

- Bilirubin less than 1.5 mg/dL (1.5-3.0 mg/dL if due to liver involvement by lymphoma)

- ALT and AST no greater than 2.5 times upper limit of normal (unless due to liver
involvement by lymphoma)

Renal

- Creatinine less than 2.0 mg/dL

- Calcium no greater than 11.5 mg/dL

Cardiovascular

- LVEF greater than 45%

Other

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception during and for 1 year after study
participation

- HIV negative

- No other malignancy except treated carcinoma in situ of the cervix or squamous cell
or basal cell skin cancer or any other surgically cured malignancy from which the
patient has been disease-free for at least 3 years

- No other concurrent serious medical condition or active infection that would preclude
ability to deliver standard prednisone, cyclophosphamide, doxorubicin, and
vincristine (CHOP) chemotherapy

PRIOR CONCURRENT THERAPY:

Biologic therapy

- No prior immunotherapy

Chemotherapy

- No prior chemotherapy

Endocrine therapy

- Prior corticosteroids allowed provided the course was no more than 2 weeks in
duration

Radiotherapy

- No prior radiotherapy

Surgery

- Not specified